Pulmatrix (PULM) stock

Worth $4.9MShares as of Aug 13

$1.35

-0.37%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score PULM. It is too small and too thinly traded for a fair Quality Score.

Healthcare · Pharma

Next2026“to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026.”Trial start · SEC filing · Aug 13

Cash$2.2M, about 2 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “into at least the fourth quarter of 2026”

Follow PULM's news. Pro members can get an alert when Pulmatrix files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PULM files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$2.2M, about 2 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “into at least the fourth quarter of 2026”

What's next for PULM, and how long its cash lasts

Next step the company has named

2026“to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026.”Trial start · SEC filing · Aug 13

What it means: when a trial begins, or reaches the stage the company named.

For Pro members: 29 filings.

Cash runway Jun 30 balance sheet

About 2 quarters

$2.2M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into at least the fourth quarter of 2026” (8-K, Dec 18, 2025). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed May 17, 2024)
At-the-market share sales program (S-3, filed May 17, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when PULM files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

PULM's latest filings

A shareholder vote8-K, filed Oct 27
Prospectus for a sale of securities424B3, filed Oct 26
Quarterly report10-Q, filed Aug 13

12 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why PULM isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. PULM is worth about $4.9M and trades about 41,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.